COMPOSITIONS AND METHODS RELATED TO INHIBITORS OF JAK KINASE
申请人:EP PHARMA, INC.
公开号:US20150087621A1
公开(公告)日:2015-03-26
Embodiments are directed to JAK kinase inhibiting prodrug compounds of Formula Ib, containing a promoiety that results in alcohol derivative of the parent compound upon removal and methods of using an effective amount of said prodrug compounds in the treatment of a JAK-mediated disease or disorder in a subject. Preferred promoieties include phosphate, phosphonate, phosphate salt, sulfate, or sulfate salt.